Advances in immunotherapy for cancer treatment: A literature review
Authors:
- Luis Miguel Carvalho MendesLMLuis Miguel Carvalho Mendes
- Lucas Arruda LinoLLLucas Arruda Lino
- Vinicius Brasil TeixeiraVTVinicius Brasil Teixeira
- Vithoria Maria Bernieri IffertVIVithoria Maria Bernieri Iffert
- Mariana Carrilho Soares BravoMBMariana Carrilho Soares Bravo
- Glamar Cunha da SilvaGSGlamar Cunha da Silva
- Tarciana Maria BordignonTBTarciana Maria Bordignon
- Bruna Rocha PereiraBPBruna Rocha Pereira
- Eduarda Emilly Silva CostaECEduarda Emilly Silva Costa
- Rosane Pereira MedeirosRMRosane Pereira Medeiros
- Dyego Lopes MatosDMDyego Lopes Matos
Open Access
- 2 September 2024
- journal article
- Published by Research, Society and Development in Research, Society and Development
- Vol. 13 (9)
Abstract
Immunotherapy has emerged as a revolutionary approach in cancer treatment, offering new hope for patients with previously intractable types of cancer. This article reviews recent advances in immunotherapy, highlighting key developments and their clinical implications. The review covers immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) therapies, therapeutic cancer vaccines, and the combination of immunotherapies with other treatment modalities. Checkpoint inhibitors, such as anti-CTLA-4 and anti-PD-1/PD-L1 antibodies, have shown significant efficacy in various cancers, including melanoma and non-small cell lung cancer. CAR-T cell therapies have shown promising results in hematologic cancers, while therapeutic vaccines have the potential to induce robust and durable immune responses. The combination of immunotherapies with chemotherapy, radiotherapy, and targeted therapies is being explored to enhance efficacy and overcome treatment resistance. Despite the advances, significant challenges remain, including treatment resistance and side effects. Continuous research is essential to better understand the mechanisms of action of immunotherapy and develop new strategies to overcome current challenges. With the advancement of science and technology, immunotherapy has the potential to become an increasingly effective and widely used therapeutic approach in cancer treatment.Keywords
This publication has 16 references indexed in Scilit:
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic FactorsImmunity, 2016
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and ToleranceTrends in Immunology, 2016
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityNature, 2015
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012